BioMEMS The Market aspects of Oligonucleotide-Chips, Products and Applications, Competition, January 21, 2016
Curator: Gérard LOISEAU, ESQ
BioMEMS
The Market aspects of Oligonucleotide-Chips, Products, Applications, Competition
January 21, 2016
2015-2020
The oligonucleotide synthesis market is expected to reach USD 1.918.6Billion at a CAGR of 10.1% by 2020 from USD 1.078.1Billion in 2015.
SOURCE
MARKETSANDMARKETS marketsandmarkets.com/
PLAYERS
- Agilent Technologies Inc.
- BioAutomation Corp.
- Biosearch Technologies
- Gen9 Inc.
- GenScript Inc.
- Illumina Inc.
- Integrated DNA Technologies
- New England Biolabs Inc.
- Nitto Denko Avecia Inc.
- OriGene Technologies Inc.
- Sigma-Aldrich Corporation
- Thermo Fisher Scientific Inc.
- TriLink Biotechnologies
Agilent Technologies CA NYSE :A
- Agilent was created as a spin off from Hewlett-Packard Company in 1999.
- Agilent Technologies Inc. is engaged in the life sciences, diagnostics and applied chemical markets. The Company provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company has three business segments:
the life sciences and applied markets business,
the diagnostics and genomics business, and
the Agilent Cross Lab business
- The Company’s life sciences and applied markets business segment brings together the Company’s analytical laboratory instrumentation and informatics.
- The Company’s diagnostics and genomics business segment consists of three businesses: the Dako business, the genomics business and the nucleic acid solutions business.
- The Company’s Agilent Cross Lab business segment combines its analytical laboratory services and consumables business
SOURCE
PRODUCTS AND SERVICES
https://www.agilent.com/en-us/default#collapse-0
- October 09, 2015 03:21 PM Eastern Daylight Time
- CARPINTERIA, Calif.–(BUSINESS WIRE)–Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, today announced the U.S. Food and Drug Administration has approved a new test that can identify PD-L1 expression levels on the surface of non-small cell lung cancer tumor cells and provide information on the survival benefit with OPDIVO® (nivolumab) for patients with non-squamous NSCLC.
SOURCE
BUSINESS WIRE busibesswire.com/
BioAutomation Corp. TX
PRODUCTS AND SERVICES
- DNA and RNA synthesis reagents for the MerMades
Note: The MerMade 192E Oligonucleotide synthesizer is designed to synthesize DNA, RNA & LNA oligonucleotides in a column format
PARTNERSHIPS
- HONGENE BIOTECH : BIOAUTOMATION is the exclusive distributor for the Americas
- EMD MILLIPORE
- BIOSEARCH TECHNOLOGIES
DISTRIBUTORS
- LINK TECHNOLOGIES : UK
- AME BIOSCIENCE : UK
- BOSUNG SCIENCE : KOREA
- DNA CHEM : CHINA
- WAKO : JAPAN
- ACE PROBE : INDIA
SOURCE
Biosearch Technologies CA
PRODUCTS
- qPCR & SNP Genotyping
- Custom Oligonucleotides
- – highly sophisticated oligonucleotides
- – simple PCR primers
- Oligos in Plates
- RNA FISH
- Synthesis Reagents
- Immunochemicals
- Primers
- Probes
- Large-Scale Synthesis Oligos
- Intermediate-Scale Synthesis Oligos
SERVICES
- GMP & Commercial Services
- OEM & Kit Manufacturing
- qPCR Design Collaborations
DISTRIBUTORS
Argentina | Australia | Austria | Brazil | Canada |Chile | China | Colombia | Czech Republic | Denmark | Ecuador | Finland | Germany |Hong Kong | Israel | Italy | Japan | Korea | Malaysia | Mexico | New Zealand | Norway | Paraguay | Peru| Philippines | Poland | Romania | Singapore | South Africa | Spain | Sweden |Switzerland | Taiwan ROC | Thailand | Turkey | United Kingdom | Uruguay | Vietnam
SOURCE
biosearchtech.com/
Gen9 Inc. MA
PRODUCTS
Gen9 is building on advances in synthetic biology to power a scalable fabrication capability that will significantly increase the world’s capacity to produce DNA content. The privately held company’s next-generation gene synthesis technology allows for the high-throughput, automated production of DNA constructs at lower cost and higher accuracy than previous methods on the market. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels.
SERVICES
- Synthetic Biology
- Gene Synthesis Services
- Variant Libraries
- Gene Sequence Design Services
INVESTORS
- Agilent Technologies : Private Equity
- CAMBRIDGE, Mass. and SANTA CLARA, Calif. — April 24, 2013 —Gen9 Receives $21 Million Strategic Investment from Agilent Technologies
SOURCE
gen9bio.com/
GenScript Inc. NJ
- GenScript is the largest gene synthesis provider in the USA
- GenScript Corporation, a biology contract research organization, provides biological research and drug discovery services to pharmaceutical companies, biotech firms, and research institutions in the United States, Europe, and Japan. It offers bio-reagent, custom molecular biology, custom peptide, protein production, custom antibody production, drug candidates testing, assay development and screening, lead optimization, antibody drug development, gene synthesis, and assay-ready cell line production services.
- The company also offers molecular biology, peptide, protein, immunoassay, chemicals, and cell biology products. It offers its products through distributors in Tokyo, Japan; and Seoul, Korea. GenScript Corporation has a strategic partnership with Immunologix, Inc. The company was founded in 2002 and is based in Piscataway, New Jersey. It has subsidiaries in France, Japan, and China.
Note: As of October 24, 2011, Immunologix, Inc. was acquired by Intrexon Corporation. Immunologix, Inc. develops and produces antibody-based therapeutics for various biological targets. It produces human monoclonal antibodies against viral, bacterial, and tumor antigens, as well as human auto antigens.
Intrexon Corporation, founded in 1998, is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy, Environment and Consumer sectors to create biologically based products that improve quality of life and the health of the planet.
PRODUCTS AND SERVICES
- Gene synthesis
- Antibody services
- Protein Services
- Peptide services
INVESTORS
Note: The Balloch Group (‘TBG’) was established in 2001 by Howard Balloch (Canada‘s ambassador to China from 1996 to 2001). TBG has since grown from a market-entry consultancy working with North American clients in China to a leading advisory and merchant banking firm serving both domestic Chinese companies and multinational corporations. TBG was ranked as the number one boutique investment bank in China by ChinaVenture in 2008.
Kleiner, Perkins, Caufield and Byers
Illumina Inc. CA
Monica Heger : SAN FRANCISCO (GenomeWeb) – Illumina today announced two new next-generation sequencing platforms, a targeted sequencing system called MiniSeq and a semiconductor sequencer that is still under development.
Illumina disclosed the initiatives during a presentation at the JP Morgan Healthcare conference held here today. During the presentation, Illumina CEO Jay Flatley also announced a new genotyping array called Infinium XT; a partnership with Bio-Rad to develop a single-cell sequencing workflow; preliminary estimates of its fourth-quarter 2015 revenues; and an update on existing products. The presentation followed the company’s announcement on Sunday that it has launched a new company called Grail to develop a next-generation sequencing test for early cancer detection from patient blood samples.
The MiniSeq system, which is based on Illumina’s current sequencing technology, will begin shipping early this quarter and has a list price of $49,500. It can perform a variety of targeted DNA and RNA applications, from single-gene to pathway sequencing, and promises “all-in” prices, including library prep and sequencing, of $200 to $300 per sample, Flatley said during the JP Morgan presentation.
SOURCES
http://investor.biospace.com/biospace/quote?Symbol=ILMN
PRODUCTS AND SERVICES
- Mid to large scale manufacturing assets
- Analytical Labs
- Pre-clinical
- Clinical
- Launched products
COMPETITORS
https://finance.yahoo.com/q/co?s=ILMN+Competitors Tue, Feb 2, 2016, 2:16pm EST – US Markets
| ILMN | PVT1 | AFFX | LMNX | Industry | |
|---|---|---|---|---|---|
| Market Cap: | 22.75B | N/A | 1.13B | 835.66M | 134.14M |
| Employees: | 3,700 | 10,000 | 1,200 | 745 | 45.00 |
| Qtrly Rev Growth (yoy): | 0.14 | N/A | -0.01 | 0.07 | 0.18 |
| Revenue (ttm): | 2.14B | 3.80B1 | 357.74M | 235.37M | 8.47M |
| Gross Margin (ttm): | 0.73 | N/A | 0.63 | 0.71 | 0.58 |
| EBITDA (ttm): | 770.84M | N/A | 46.64M | 52.99M | -12.31M |
| Operating Margin (ttm): | 0.30 | N/A | 0.08 | 0.17 | -1.62 |
| Net Income (ttm): | 510.36M | 430.90M1 | 11.22M | 39.29M | N/A |
| EPS (ttm): | 3.42 | N/A | 0.13 | 0.93 | -0.34 |
| P/E (ttm): | 45.43 | N/A | 104.40 | 20.91 | 25.33 |
| PEG (5 yr expected): | 2.68 | N/A | 4.66 | 0.55 | N/A |
| P/S (ttm): | 10.87 | N/A | 3.13 | 3.45 | 13.65 |
Pvt1 = Life Technologies Corporation (privately held)
AFFX = Affymetrix Inc.
LMNX = Luminex Corporation
Integrated DNA Technologies (IDT) IOWA + CA
Integrated DNA Technologies, Inc. (IDT), the global leader in nucleic acid synthesis, serving all areas of life sciences research and development, offers products for a broad range of genomics applications. IDT’s primary business is the production of custom, synthetic nucleic acids for molecular biology applications, including qPCR, sequencing, synthetic biology, and functional genomics. The company manufactures and ships an average of 44,000 custom nucleic acids per day to more than 82,000 customers worldwide. For more information, visit idtdna.com.
PRODUCTS AND SERVICES
- DNA & RNA Synthesis
- Custom DNA Oligos 96- & 384-Well Plates Ultramer Oligos Custom RNA Oligos SameDay Oligos HotPlates ReadyMade Primers Oligo Modifications Freedom
- Dyes GMP for Molecular Diagnostics Large Scale Oligo Synthesis
Note : Skokie, IL – December 1, 2015. Integrated DNA Technologies Inc. (“IDT”), the global leader in custom nucleic acid synthesis, has entered into a definitive agreement to acquire the oligonucleotide synthesis business of AITbiotech Pte. Ltd. in Singapore (“AITbiotech”). With this acquisition, IDT expands its customer base across Southeast Asia making it possible for these additional customers to now have access to its broad range of products for genomic applications. AITbiotech will continue operations in its other core business areas.
New England Biolabs Inc.
MA
PRODUCTS AND SERVICES
- Restriction Endonucleases
- PCR, Polymerases & Amplification Technologies
- DNA Modifying Enzymes
- Library Preparation for Next Generation Sequencing
- Nucleic Acid Purification
- Markers & Ladders
- RNA Reagents
- Gene Expression
- Cellular Analysis
SOURCE
Nitto Denko Avecia Inc. MA
With over 20 years of experience in oligonucleotide development and production, and over 1000 sequences manufactured, Avecia has played an integral role in the advancing oligo therapeutic market. Our mission is to continue to build value for our customers, as they progress through drug development into commercialization. And as a member of the Nitto Denko Corporation (nitto.com), Avecia is committed to the future of the oligonucleotide market. We are driven by innovative ideas and flexible solutions, designed to provide our customers with the best in service, quality, and technology.
SOURCE
Note : 1918 Nitto Electric Industrial Co., Ltd. forms in Ohsaki, Tokyo, to produce electrical insulating materials in Japan.
2011 Acquires Avecia Biotechnology Inc. in the U.S.A.
OriGene Technologies Inc. CA
OriGene Technologies, Inc. develops, manufactures, and sells genome wide research and diagnostic products for pharmaceutical, biotechnology, and academic research applications. The company offers cDNA clones, including TrueORF cDNA, viral ORF, destination vectors, TrueClones (human), TrueClones (mouse), organelle marker plasmids, MicroRNA tools, mutant and variant clones, plasmid purification kits, transfection reagents, and gene synthesis service; and HuSH shRNA, siRNA, miRNA, qPCR reagents, plasmid purification products, transfection reagents, PolyA+ and total RNA products, first-strand cDNA synthesis, and CRISPR/Cas9 genome products. It also provides proteins and lysates, such as purified human proteins, over-expression cell lysates, mass spectrometry standard proteins, and protein purification reagents; UltraMAB IHC antibodies, TrueMAB primary antibodies, anti-tag and fluorescent proteins, ELISA antibodies, luminex antibodies, secondary antibodies, and controls and others; and anatomic pathology products, including IHC antibodies, detection systems, and IHC accessories
The company offers luminex and ELISA antibody pairs, autoantibody profiling arrays, ELISA kits, cell assay kits, assay reagents, custom development, and fluorogenic cell assays; TissueFocus search tools; tissue sections; tissue microarrays, cancer protein lysate arrays, TissueScan cDNA arrays, tissue blocks, and quality control products, as well as tissue RNA, DNA, and protein lysates; and lab essentials. Its research areas include cancer biomarker research, RNAi, pathology IHC, stem cell research, ion channels, and protein kinase products. The company provides gene synthesis and molecular biology services, genome editing, custom cloning, custom shRNA, purified protein, monoclonal antibody development, and assay development. It sells its products through distributors worldwide, as well as online. OriGene Technologies, Inc. was incorporated in 1995 and is based in Rockville, Maryland.
SOURCE
PRODUCTS AND SERVICES
- cDNA Clones Human, mouse, rat Expression validated
- RNAi shRNA, siRNA microRNA & 3’UTR clones
- Gene Synthesis Codon optimization Variant libraries
- Real-time PCR Primer pairs, panels SYBR green reagents
- Lab Essentials DNA/RNA purification kits Transfection reagents
- Anatomic Pathology UltraMAB antibodies Specificity validated
- Recombinant Proteins 10,000 human proteins from mammalian system
- Antibodies TrueMAB primary antibodies Anti-tag antibodies
- Assays and Kits ELISA & Luminex antibodies Autoantibody Profiling Array
- Cancer & Normal Tissues Pathologist verified gDNA, RNA, sections, arrays
SOURCE
origene.com/
Sigma-Aldrich Corporation MI
Louis, MO – November 18, 2015 Merck KGaA, Darmstadt, Germany, Completes Sigma-Aldrich Acquisition
Merck KGaA today announced the completion of its $17 billion acquisition of Sigma-Aldrich, creating one of the leaders in the $130 billion global industry to help solve the toughest problems in life science.
Press Release: 18-Nov-2015
Letter to our Life Science Customers from Dr. Udit Batra
The life science business of Merck KGaA, Darmstadt, Germany brings together the world-class products and services, innovative capabilities and exceptional talent of EMD Millipore and Sigma-Aldrich to create a global leader in the life science industry.
“Everything we do starts with our shared purpose – to solve the toughest problems in life science by collaborating with the global scientific community.
This combination is built on complementary strengths, which will enable us to serve you even better as one organization than either company could alone.
This means providing a broader portfolio with a catalog of more than 300,000 products, including many of the most respected brands in the industry, greater geographic reach, and an unmatched combination of industry-leading capabilities.”
PRODUCTS AND SERVICES
http://www.sigmaaldrich.com/configurator/servlet/DesignCenter?btnOpen_0.x=1
http://www.sigmaaldrich.com/content/dam/sigma-aldrich/common/quality-products.jpg
Thermo Fisher Scientific Inc. MA NYSE :TMO
Thermo Fisher Scientific Inc. is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The company operates through four segments: Life Sciences Solutions, provides reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of disease; Analytical Instruments, provides instruments, consumables, software and services that are used in the laboratory; Specialty Diagnostics, offers diagnostic test kits, reagents, culture media, instruments and associated products, and Laboratory Products and Services, offers self-manufactured and sourced products for the laboratory.
SOURCE
PRODUCTS AND SERVICES
- Oligos Value – Standard – Plate
- Primers
- Probes
- Nucleotides
BRANDS
- THERMO SCIENTIFIC
- APPLIED BIOSYSTEMS
- INVITROGEN
- FISHER SCIENTIFIC
- UNITY LAB SERVICES
PARTNERSHIPS
AFFYMETRIX : NASDAQ : AFFX : affymetrix.com/
WALTHAM, Mass. & SANTA CLARA, Calif.–(BUSINESS WIRE)–Jan. 8, 2016– Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and Affymetrix Inc. (NASDAQ:AFFX), a leading provider of cellular and genetic analysis products, today announced that their boards of directors have unanimously approved Thermo Fisher’s acquisition of Affymetrix for $14.00 per share in cash. The transaction represents a purchase price of approximately $1.3 billion.
SOURCE
TriLink Biotechnologies CA
PRODUCTS
Oligonucleotides
- DNA Oligos
- RNA Oligos
- Modified Oligos
- Specialty Oligos
Nucleotides
- NTPs (Nucleoside Triphosphates)
- Biphosphates
- Monophosphates
SERVICES
- Custom Chemistry
- Reagents
- Aptamers
PARTNERSHIPS
- LIFE TECHNOLOGIES,
- TERMO FISHER SCIENTIFIC since July 2015 thermofisher.com/
- GENMARK genmarkdx.com/
SOURCE
Other related articles published in this Open Access Online Scientific Journal include the following:
Gene Editing: The Role of Oligonucleotide Chips
http://pharmaceuticalintelligence.com/2016/01/07/gene-editing-the-role-of-oligonucleotide-chips/
Gene Editing for Exon 51: Why CRISPR Snipping might be better than Exon Skipping for DMD
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aptubman
Arav Gandhi
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
zraviv06
zs22
Leave a Reply